Evaluating Harmony Biosciences: Insights From 8 Financial Analysts
Evaluating Harmony Biosciences: Insights From 8 Financial Analysts
評估和諧生物科學：來自8位金融分析師的見解
Harmony Biosciences (NASDAQ:HRMY) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
和諧生物科學（納斯達克股票代碼：HRMY）在上個季度接受了8位分析師的分析，揭示了從看漲到看跌的一系列觀點。
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
下表簡要介紹了他們最近的收視率，展示了過去30天中不斷變化的情緒，並將其與前幾個月進行了比較。
Insights from analysts' 12-month price targets are revealed, presenting an average target of $42.62, a high estimate of $53.00, and a low estimate of $28.00. This current average reflects an increase of 11.42% from the previous average price target of $38.25.
分析師12個月目標股價的見解已經公佈，平均目標股價爲42.62美元，最高估計爲53.00美元，低估值爲28.00美元。目前的平均價格比之前的平均目標價38.25美元增長了11.42％。
Breaking Down Analyst Ratings: A Detailed Examination
分解分析師評級：詳細審查
In examining recent analyst actions, we gain insights into how...
在研究分析師最近的行...
登入免費觀看全文
登入/註冊